Background--Cyclic guanosine monophosphate-protein kinase G-phosphodiesterase 5 signaling may be disturbed in heart failure (HF) with preserved ejection fraction, contributing to cardiac remodeling and dysfunction. The purpose of this study was to manipulate cyclic guanosine monophosphate signaling using the dipeptidyl-peptidase 4 inhibitor saxagliptin and phosphodiesterase 5 inhibitor tadalafil. We hypothesized that preservation of cyclic guanosine monophosphate cGMP signaling would attenuate pathological cardiac remodeling and improve left ventricular (LV) function.
D
iastolic dysfunction can play an important role in heart failure with preserved ejection fraction (HFpEF), with many factors contributing to the disease including left ventricular (LV) hypertrophy, myocardial fibrosis, impaired calcium reuptake, and energetic abnormalities. [1] [2] [3] [4] Cyclic guanosine monophosphate (cGMP) levels modulate many signaling pathways regulating diastolic function and may inhibit ventricular hypertrophy and stiffness while promoting diastolic relaxation. [5] [6] [7] [8] There is growing evidence the cGMP signaling cascade is disturbed in HFpEF patients and could contribute to diastolic dysfunction. 4, 5, 9, 10 cGMP signaling may be reduced in HF via 3 primary cellular mechanisms: (1) enhanced catabolism through upregulation of specific phosphodiesterases (PDEs); (2) decreased synthesis via impaired natriuretic peptide activation of transmembrane-associated particulate guanylate cyclase receptors; or (3) decreased nitric oxide (NO) stimulation of and/or responsiveness by soluble guanylate cyclase. 5 One alternative method to potentially impact cGMP signaling is by inhibition of the enzyme dipeptidyl-peptidase 4 (DPP-4). DPP-4 cleaves the N-terminal portion from intact brain natriuretic peptide (BNP) , yielding BNP that displays significantly reduced myocardial, vascular, and renal effects versus the full peptide. [11] [12] [13] DPP-4 has also been shown to reduce NO bioavailability. 14 The positive effects and recent US Food and Drug Administration approval of LCZ696 (a combination angiotensin receptor antagonist and neprilysin inhibitor) on reducing natriuretic peptide cleavage products highlight the therapeutic efficacy of preserving intact BNP in HF. 15 The current study expands on this concept to assess and contrast efficacy of both PDE5 and DPP-4 inhibition to promote cGMP. Therefore, the purpose of this study was to assess the effects of promoting cGMP signaling on LV remodeling and function via 2 mechanisms: (1) stimulating cGMP synthesis with the DPP-4 inhibitor saxagliptin; and (2) reducing cGMP catabolism with the PDE5 inhibitor tadalafil. We performed these experiments in aortic-banded miniature swine exhibiting key clinical characteristics of HFpEF including preserved ejection fraction at rest, diastolic dysfunction, depressed contractile reserve, LV fibrosis, and lung congestion. [16] [17] [18] [19] Although we originally hypothesized that preservation of cGMP levels would attenuate pathological remodeling and preserve normal LV function in an experimental setting of HF, our results suggest the myocardial effects of saxagliptin and tadalafil occur independently of increasing downstream protein kinase G (PKG) activity.
Methods Aortic Banding
HF was induced with aortic banding over a period of 24 weeks as previously reported by our laboratory [16] [17] [18] with modifications. These modifications included the use of younger pigs (3 months old) and a reduced afterload (50 mm Hg). Intact male Yucatan miniature swine were matched for body mass (10-15 kg) and cardiac function and divided into 4 experimental groups: nonbanded untreated control (CON; n=6), aortic-banded untreated HF (HF; n=7), aortic-banded tadalafiltreated HF (HF-TAD; n=8), and aortic-banded saxagliptintreated HF (HF-SAX; n=8). The aortic band was placed around the ascending aorta (proximal to the brachiocephalic artery) and a systolic trans-stenotic gradient of %50 mm Hg was achieved (50AE1, 50AE3, 48AE2 for HF, HF-TAD, and HF-SAX, respectively, P=NS). The aortic band was set under equivalent hemodynamic conditions for all pigs and characterized by a peripheral vascular mean arterial pressure of %90 mm Hg (90AE1, 92AE1, 90AE1 for HF, HF-TAD and HF-SAX, respectively, P=NS) under anesthesia using phenylephrine (IV 1-3 lg kg À1 min À1 ) at a heart rate of %100 beats/min (96AE6, 
Terminal Studies
Animals were initially anesthetized with a telazol (5 mgÁkg À1 )/xylazine (2.25 mgÁkg À1 ) mix and maintained on propofol (6-10 mgÁkg À1 Ámin À1 with bolus as needed) as previously described. 17 Heparin was given with an initial loading dose of 300 U/kg IV, followed by maintenance of 100 U/kg each hour. A median sternotomy was performed, and pressure-volume (P-V) loops were measured utilizing a calibrated 5F admittance-based ADVantage catheter (Transonic Systems, Inc.; Ithaca, NY) positioned in the LV via a small apical incision. A 14F balloon occlusion catheter was advanced to the inferior vena cava at the level of the apex of the heart via the deep femoral vein.
In Vivo Cardiovascular Function P-V experiments were conducted as previously published. 18 Briefly, after the catheters were placed, animals were allowed to stabilize for 10 minutes until a resting, baseline homeostasis was established. P-V loops were recorded under conditions of reducing preload achieved through transient occlusion of the inferior vena cava via inflation of the balloon catheter. Indices of LV function were generated using a minimum of 10 consecutive cardiac cycles with Lab Scribe software (iWorx; Dover, NH) including the following: heart rate, LV end-systolic and diastolic volume, LV end-systolic and diastolic pressure), ejection fraction, and stroke volume. Indices of LV contractility and stiffness including the endsystolic pressure-volume relationship (ESPVR), preload recruitable stroke work (PRSW), and the end-diastolic pressurevolume relationship (EDPVR) were measured using at least 15 consecutive cardiac cycles of constantly reducing preload. A quadratic fit was used to determine ESPVR and PRSW, and an exponential fit was used to calculate EDPVR. 20 Plasma tadalafil levels were modeled, and a dose of 2 mgÁkg À1 twice/day (total 4 mgÁkg À1 Áday À1 ) was chosen as plasma steady-state trough levels >50 ng/mL were confirmed in all animals.
Pharmacokinetics-Tadalafil and Saxagliptin

Transthoracic M-Mode and 2-Dimensional Speckle Tracking Echocardiography
Transthoracic echocardiography was performed with animals under telazol/xylazine sedation (2.25/1.12 mgÁkg À1 ) in the supine/right lateral position 6 months postbanding as previously described. [17] [18] [19] Short-axis 2-dimensional M-mode images were recorded at the midpapillary level using a GE Vivid I Ultrasound system with a 2.5-MHz transducer, and all analyses were performed offline using GE EchoPac Software. LV chamber dimensions including LV internal diastolic dimension (LVIDd), LV internal systolic dimension, LV wall thickness (LV systolic wall thickness; LV diastolic wall thickness, LV WTd), and interventricular septum wall thickness (interventricular septum systolic wall thickness, IVS WTs; interventricular septum diastolic wall thickness, IVS WTd) were calculated from M-mode recordings. Relative wall thickness (normalized to LVIDd) was calculated as (LV WTd+IVS WTd)/LVIDd91000. Six segments of the LV and septum were generated from apical 4-chamber and short-axis 2-dimensional views (acquired at the mitral-valve and apex levels) and averaged to determine global strain, strain rate, and displacement in the longitudinal, radial, and circumferential directions over 3 cardiac cycles using 2-dimensional speckle tracking. 17, 18, 21 Torsion was calculated as the difference between mitral and apical end-systolic rotation (degrees) and normalized to both LV hypertrophy (wall thickness) and end-diastolic chamber length as previously described.
17,22
Cardiomyocyte Morphology and Functional Measures LV cardiac myocytes were enzymatically isolated from LV wedge preparations of excised hearts as previously described. 16 
Protein Levels
Western blot analysis was used to determine protein levels as previously described 6, 16, 19, 24 in buffer containing 150 mmol/ L NaCl, 10 mmol/L Tris pH 7.4, 1 mmol/L EDTA, 1% Triton X-100, and protease/phosphatase inhibitors (Halt, Thermo Scientific). After sonication, the lysates were centrifuged at 17 000g for 10 minutes to remove insoluble material and sample concentration was then determined by Bradford assay (Bio-Rad). 
Atrial/BNP and Neuropeptide Y (NPY) Plasma Levels
Plasma atrial natriuretic peptide (ANP) and BNP were measured as previously described. [25] [26] [27] Blood was drawn into EDTA tubes and chilled until centrifuged at 750 g for 10 minutes at 4°C. One milliliter of plasma was aliquoted into 12975-mm polystyrene tubes and frozen until assayed. One milliliter of plasma was extracted using C-18 Bond Elut cartridges. After washing cartridges with 4 mL 100% methanol and 4 mL water, plasma was applied and cartridges were washed again with 2 mL saline, 6 mL water, and 1 mL 100% methanol. ANP was eluted with 2 mL 75% methanol and 1% trifluoroacetic acid. Eluates were dried/concentrated on a Savant speed vac overnight, and resuspended in 300 lL assay buffer. One hundred microliters of standards and samples were incubated with 100 lL diluted (1:150 000) anti-human ANP (Phoenix Pharmaceuticals, Mountain View, CA) at 4°C. After 18 hours, 100 lL (10 000 counts) I 125 -labeled ANP is added and incubated at 4°C. After 18 hours incubation, a second antibody was added to all samples to separate the free and bound fractions. Samples were centrifuged, the free fraction was aspirated, and the bound fraction was counted on a gamma counter. A standard curve was generated and used to calculate the concentrations of the unknown samples and reported in pg/mL. The range of the standard curve is 2 to 500 pg/mL. Inter-and intra-assay variability was 9% and 6%, respectively. Recovery of 64 pg was 81AE2%. Cross-reactivity was <1% with N-ANP, BNP, C-type natriuretic peptide (CNP), endothelin, and adrenomedullin. BNP was eluted from the cartridges with 2 mL of 90% methanol in 1% trifluoroacetic acid. Samples were dried on a Savant Speed Vac concentrator. The eluates were dried and reconstituted in 300 lL assay buffer. The radioimmunoassay used for this assay was a nonequilibrium assay from Phoenix Pharmaceuticals (Mountain View, CA) that uses an antibody to human, rat, or canine BNP. One hundred microliter standards or samples were incubated with 100 lL diluted antibody for 18 to 24 hours at 4°C. After incubation, 10 000 counts of iodinated (I 125 ) BNP were added and incubated at 4°C. After 18 hours incubation, 100 lL of second antibody (goat antirabbit) and 100 lL normal rabbit serum were added to all samples to separate the free and bound fractions. After 1.5-hour room temperature incubation, samples were centrifuged, the free fraction was aspirated, and the discarded and bound fraction was counted on a gamma counter. A standard curve was generated and used to calculate the concentrations of the unknown samples and reported in pg/mL. The range of the standard curve was 0.5 to 128 pg/mL, recovery was 73%, and inter-and intra-assay variability was 11% and 7%, respectively. There was no cross-reactivity with ANP, CNP, or endothelin-1,2,3. NPY was eluted similarly to BNP. After resuspension in 500 lL assay buffer, 100 lL of standards and unknown samples were incubated with 100 lL rabbit-anti human NPY at 4°C overnight. After 18 hours incubation, 100 lL I 125 -labeled antigen is added and incubated overnight at 4°C.
The range of the standard curve was 5 to 1280 pg/mL, recovery was 78%, and intra-assay variability was 10%. There was no cross-reactivity with ANP, BNP or CNP, and 100% cross-reactivity with human NPY and peptide YY.
cGMP-PKG-PDE5 Activity and Protein Levels
Myocardial cGMP levels for flash-frozen LV samples were examined using a commercial EIA kit (Amersham) as previously described. 6, 24 The LV samples were homogenized in 6% trichloroacetic acid, centrifuged, and extracted with watersaturated diethyl ether. The aqueous phase was transferred, lyophilized, and the pellet resuspended in 200 lL of lysis buffer. The dissolved samples were acetylated with 20 lL of acetylation reagent, and then 50 lL of each sample were incubated with 100 lL of antiserum in a 96-well plate at 4°C. After 2 hours, 100 lL of diluted conjugate were added and incubated for 1 hour at 4°C. After washing, 200 lL of room temperature equilibrated enzyme substrate (tetramethylbenzidine) were added immediately and incubated for 30 minutes at room temperature with shaking. The color was quantified at 630 nm by spectrophotometry, and cGMP levels were normalized by total protein concentration measured by bicinchoninic acid method (Pierce). In vitro PKG activity was assayed in frozen LV samples, in the presence of cGMP and ATP, which were allowed to phosphorylate the bound substrate using a colorimetric assay kit (Cyclex) as previously described. 6, 24 Ten microliters (30 lg protein) of each sample, including PKG positive control and 90 lL of kinase reaction buffer containing cGMP and ATP, were incubated in a 96-well plate for 30 minutes at 30°C. After washing, 100 lL of horseradish peroxidase conjugated detection antibody (10H11) were added and incubated at room temperature. After 1 hour, each sample was washed and incubated with 100 lL of chromogenic substrate tetramethylbenzidine at room temperature. After 10 minutes, 100 lL of stop solution was added to each well, and the color was quantified at dual wavelengths of 450/540 nm by spectrophotometry.
In vitro PDE5 activity was assessed by fluorescence polarization assay (Molecular Probes) as previously described.
6,24 LV samples were homogenized in lysis buffer 
DPP-4 Assay
DPP-4 activity was measured at 25°C and monitored using a Shimadzu UV1650PC UV/Visible Spectrophotometer in conjunction with a Shimadzu 6-cell CPS temperature-controlled sample conveyor system. Chemical constituents of the 1-mL assay included the following: 500 lL 2X ATE (104 mmol/L ACES, 104 mmol/L Tris, and 208 mmol/L ethanolamine adjusted to pH 7.4 with 5 mol/L HCl), 500 lL 2 mmol/L substrate (Gly-Pro-p-nitro analine), and 50 lL of serum or plasma. Negative enzyme controls were set up similarly using heat-inactivated serum or plasma. A standard curve was established under the same buffer and measurement conditions using serial 2-fold dilutions of p-nitro-aniline (800 lmol/ L to 3.13 lmol/L product).
Mitochondrial Isolation, Swelling, Ca 2+ Retention Capacity, and Respiration
The isolation of cardiac mitochondrial and cytosolic fractions was carried out as previously described. 16, 19 Briefly, LV tissue was homogenized using a Dounce homogenizer in buffer containing 250 mmol/L sucrose, 10 mmol/L Tris pH 7.4, and 1 mmol/L EDTA. The homogenate was then centrifuged at 1000g for 5 minutes to pellet nuclei and unbroken cells/debris. The supernatant was then centrifuged at 10 000g for 10 minutes to pellet mitochondria, which were subsequently washed twice in EDTA-free homogenization buffer. Mitochondrial swelling, Ca 2+ retention capacity, and respiration procedures were performed as described previously. 16 
Histology and Immunohistochemistry
Cross sections of LV were formalin fixed, embedded in paraffin, and stained for assessment of collagen as previously published. 16, 19 Briefly, total collagen was visualized using
Picrosirius red staining and quantified from 4 separate fields/ animal using Image-Pro Plus analysis software (MediaCybernetics, version 6.2, Bethesda, MD) and expressed as the percent area stained.
Statistical Analysis
All data analysis was performed using SigmaPlot version 12.3 (SysStat Software Inc., San Jose, CA). Treatment comparisons were made using either repeated-measures ANOVA (RM-ANOVA) or 1-way ANOVA. Normality (Shapiro-Wilk's test) and equality of variance were confirmed prior to comparison by ANOVA. Linear regression was used to examine the relationship between collagen and NPY levels. Group differences revealed by ANOVA were found using StudentNewman-Keuls post hoc analysis. All data are meansAESE, and significance is reported at the P<0.05 level. significantly increased following treatment with tadalafil (*P<0.05 vs CON, HF, and HF-SAX). B, PKG activity was unchanged by any treatment effect. C, PDE5 protein level was unaltered by heart failure. D, Saxagliptin increased PDE5 activity compared to all other groups (*P<0.05 vs CON and HF-TAD, † P=0.058 vs HF). E, Representative Western blot of PDE5 levels. GAPDH is presented to demonstrate equivalent loading conditions. F, Treatment with saxagliptin decreased plasma DPP-4 activity compared to CON (*P<0.05 vs CON). Heart failure had no effect on DPP-4 activity. G and H, Plasma BNP (G) and ANP (H) levels were unchanged in aortic-banded groups irrespective of treatment compared to CON animals. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; cGMP indicates cyclic guanosine monophosphate; CON, control; DDP-4, dipeptidyl-peptidase 4; HF, heart failure; PDE5, phosphodiesterase-5; PKG, protein kinase G; SAX, saxagliptin; TAD, tadalafil. increased cGMP levels ( Figure 1A ) compared to the CON, HF, and HF-SAX groups. Increased cGMP in HF-TAD animals did not translate into increased PKG activity, its principal downstream effector kinase ( Figure 1B ). PDE5 protein levels were unchanged in HF or following either treatment arm ( Figure 1C ; representative Western blot Figure 1E) ; however, saxagliptin increased PDE5 activity ( Figure 1D ) compared to all other groups. DPP-4 activity was significantly decreased %70% from CON levels ( Figure 1F ), indicating our saxagliptin treatment was successful. No significant differences in plasma BNP ( Figure 1G ) or ANP ( Figure 1H ) levels were observed between groups.
Cardiac Remodeling
Body weight was significantly increased in the HF-TAD group; therefore, heart and lung morphology measures were normalized to body weight and presented in Table 1 . Global cardiac hypertrophy occurred to a similar extent in all aorticbanded groups, regardless of treatment. Increased lung weight:body weight ratio (indicative of pulmonary congestion) was observed only in the HF group compared to CON. Lung weight:body weight ratio was similar to CON animals in the HF-TAD and HF-SAX groups, suggesting these treatments were effective in preventing a clinical symptom of HF.
Representative histological sections of the LV from CON, HF, HF-SAX, and HF-TAD groups are shown in Figure 2A . Total collagen levels (Picrosirius red staining; expressed as the percent area of LV stained), indicative of increased fibrosis, was significantly increased in HF animals compared to CON ( Figure 2B ). Treatment with either saxagliptin or tadalafil prevented aortic banding-induced increases in LV collagen content. Circulating plasma NPY levels were increased in HF compared to CON animals ( Figure 2C ). Cumulative group data, indicated by the regression line, showed LV collagen content was positively correlated with NPY ( Figure 2D ). Increased plasma NPY levels and the rightward shift in NPY in relation to collagen were attenuated by both saxagliptin and tadalafil ( Figure 2C and 2D) . Fibrotic remodeling was not associated with any changes to Akt, ERK, or SAPK/JNK signaling, as no differences in the respective protein phosphorylation levels were detected ( Figure 2E and 2F) .
Assessment of LV morphology via echocardiography supports our postmortem data ( Table 2 ). Aortic banding increased diastolic wall thickness, primarily in the interventricular septal wall (IVS WTd), but did not alter LV internal diastolic dimension (LVIDd) compared to CON irrespective of treatment. Relative wall thickness (normalized to LVIDd) was also significantly elevated in all aortic-banded groups. In total, these findings reflect concentric hypertrophic remodeling.
Isolated cardiomyocyte morphology was largely consistent with our postmortem and ultrasound findings ( Table 1, CON: n=6 animals, 180 cells; HF: n=7 animals, 209 cells; HF-SAX: n=7 animals, 210 cells; HF-TAD: n=8 animals, 198 cells). Cell width was significantly increased in both HF and HF-TAD animals compared to the CON group, and cell length was also increased in HF-TAD animals. The decrease in length:width ratio observed in the HF and HF-TAD compared to CON reflects a classic cellular indicator of concentric hypertrophy. Cell width, length, and length:width ratio was the same in HF-SAX animals compared to the CON group.
Systolic Function
Resting hemodynamic and LV functional data are presented in Table 3 (representative pressure-volume loops are shown in Figure 3 ). Heart rate and end-systolic pressure were the same among all groups. End-systolic volume was decreased in both the HF and HF-TAD groups and unchanged in HF-SAX animals compared to CON. LV ejection fraction and stroke volume were equivalent in all groups, demonstrating preserved systolic function at rest in the presence of clinical markers of HF (ie, lung congestion, a hallmark feature of HFpEF). Similar to previous observations in our swine model and human HFpEF, 1,2,23 LV contractility (measured as ESPVR and PRSW) was significantly increased in HF animals compared to the CON group. Tadalafil did not prevent aortic bandinginduced increases in LV contractility and actually increased Figure 4A . A negative shortening-frequency relationship, a cellular characteristic of HF, 28 was observed in the HF group compared to CON animals at absolute lengths ( Figure 4B ; group9pacing interaction) and relative to 0.25 Hz ( Figure 4C ; group9pacing interaction). Both saxagliptin and tadalafil prevented the aortic banding-induced negative shortening-frequency relationship. However, absolute shortening was significantly reduced from CON levels in the HF-TAD group at all pacing frequencies and at 0.5 and 1.0 Hz in the HF-SAX group. A parallel decrease in calcium transient amplitude ( Figure 4D ; group9pacing interaction) was seen in the HF-TAD group compared to all other groups. Aortic banding changed LV mechanics in a manner suggesting impaired systolic function. Representative 2-dimensional speckle tracking echocardiography images illustrating global longitudinal strain are shown in Figure 5A through 5D and demonstrate the decrease in global longitudinal strain ( Figure 5E ) observed in the HF group compared to CON. This effect was also seen in HF-SAX animals. Consistent with the cardiomyocyte shortening data presented in Figure 4B , systolic mechanics were impaired to a greater extent in the HF-TAD group as global longitudinal, circumferential, and radial strain were decreased compared to all other groups ( Figure 5E ). Torsion was preserved ( Figure 5F ) or increased (when normalized to cardiac remodeling; Figure 5G -septum, Figure 5H -LV) in HF compared to CON animals. The increase in normalized torsion observed in the HF group was prevented in both HF-TAD and HF-SAX animals.
LV Diastolic Function
LV end-diastolic volume was decreased in HF and HF-TAD animals and unchanged in HF-SAX compared to the CON group (Table 3) . End-diastolic pressure, although not considered pathological (>15 mm Hg), was significantly increased in the HF-TAD group compared to all other groups. The slope of the EDPVR was significantly increased in the HF compared to CON group and indicative of global LV diastolic dysfunction. Neither saxagliptin nor tadalafil prevented aortic bandinginduced diastolic impairment.
As a cellular surrogate of diastolic function, changes to resting cardiomyocyte sarcomere length in response to increased frequency of stimulation were examined. A significant pacing-induced decrease in absolute ( Figure 4E group9pacing interaction) diastolic sarcomere length was observed in the HF and HF-TAD groups compared to CON. This finding, indicative of impaired diastolic relaxation, was prevented by saxagliptin treatment. Representative 2-dimensional speckle tracking echocardiography images illustrating early and late peak longitudinal diastolic strain rate are shown in Figure 6A through 6D. LV global longitudinal strain rate was reduced in HF compared to CON animals ( Figure 6E ), illustrating that LV mechanics associated with early diastolic filling were consistent with our LV and cellular data. Early diastolic mechanics were impaired to a greater degree following treatment with tadalafil, and evident as reduced global longitudinal ( Figure 6E ) and apical circumferential strain rate ( Figure 6F ) compared to both CON and HF animals. Saxagliptin prevented, and in some cases improved, alterations to early diastolic LV mechanics observed in the HF group. Decreased global longitudinal strain rate was attenuated in the HF-SAX group ( Figure 6E) , and apical circumferential strain rate ( Figure 6F ) and untwisting ( Figure 6G) were increased above normal CON levels.
Global longitudinal strain rate during late diastole is presented in Figure 6H . Compared to CON, both HF and HF-TAD animals showed increased global longitudinal strain rate during late diastole. Saxagliptin prevented this increase, as late diastolic longitudinal strain rate was reduced below CON levels.
LV Mitochondrial Function
Our results indicate evidence of early mitochondrial dysfunction. Using Complex I substrates ( Figure 7A ), respiratory control, as measured by State3/State2 and State3/State4 ratios, remained unchanged in the various groups. However, using Complex-II substrates ( Figure 7B ), respiratory control was decreased in HF-TAD animals compared to the CON group, suggestive of respiratory uncoupling. In line with this result, previous work has shown that tadalafil can affect skeletal muscle citrate synthase, which along with Complex II constitutes a portion of Krebs cycle enzymes. 29 We next assessed MPT, another index of mitochondrial dysfunction. There were no modifications in expression of the proteins thought to comprise the MPT pore including mitochondrial Complex V, Complex I, cyclophilin-D, mitochondrial phosphate carrier, adenine nucleotide translocase, voltage-dependent anion channel, and Complex II ( Figure 7C and 7D ). Regarding indices of MPT, we did not observe any changes in calciuminduced mitochondrial swelling ( Figure 7E ). However, calciumretention capacity, a more sensitive MPT index, was decreased in HF animals compared to the CON group ( Figure 7F ) and indicative of increased susceptibility to Ca 2+ -induced MPT. Interestingly, this decrease was not observed in HF-SAX or HF-TAD animals. Saxagliptin prevented aortic banding-induced mitochondrial dysfunction.
Discussion
In this study, we examined the therapeutic effect of manipulating the cGMP signaling pathway on LV remodeling and function in aortic-banded mini-swine displaying key clinical characteristics of HFpEF. Two separate pharmacological methods were tested: (1) promoting cGMP synthesis with the DPP-4 inhibitor saxagliptin, and (2) preventing cGMP catabolism via the PDE5 inhibitor tadalafil. Our results show a number of novel findings: (1) increased LV collagen deposition observed in the HF group was attenuated by both drugs and correlated with circulating plasma NPY levels; (2) LV global and cellular function were distinctly altered in a drug-dependent fashion, with saxagliptin better preserving integrated LV systolic and diastolic function compared to tadalafil; and (3) although both drug treatments modified the cGMP-PKG-PDE5 signaling axis distinctly with saxagliptin increasing PDE5 activity and tadalafil increasing cGMP levels, neither resulted in a downstream increase in PKG activity.
Our data indicate saxagliptin and tadalafil had distinct effects on the LV functional profile that characterizes HFpEF, with saxagliptin providing the greatest benefit. As shown by our lab 17, 23 and others, [30] [31] [32] aortic-banded swine develop significant LV hypertrophy. Regarding our hypothesis, changes in cGMP levels and PDE5 activity following treatment with tadalafil or saxagliptin, respectively, did not limit LV hypertrophic remodeling in response to chronic pressure overload from a gross morphological perspective. However, both saxagliptin and tadalafil prevented aortic banding-induced increases in LV collagen deposition, suggesting that treatment with either drug may limit detrimental and irreversible myocardial fibrosis. Drug-related prevention of LV fibrotic remodeling was significantly correlated with altered levels of a known DPP-4 substrate, neuropeptide Y (NPY). NPY levels are increased in disease states in which sympathetic nervous system activation is enhanced, such as diabetic or stress cardiomyopathy, 33, 34 and our results show a significant increase in circulating plasma NPY in the HF group. Neuropeptide Y is positively correlated in humans with LV wall thickness, LV mass index, and associated with a higher risk of concentric hypertrophy. 35, 36 A new study by Santos-Gallego et al showed that the involvement of Akt and ERK signaling is integral to cardiac remodeling in the remote myocardium of infarcted swine. 37 Our findings indicate pressure-overloadinduced hypertrophy is not associated with changes to Akt or ERK activation and are similar to recent work demonstrating chronic NPY infusion induces diastolic dysfunction and concurrent pathological cardiac hypertrophy, including increased fibrosis, independent of activated Akt/ERK signaling. 38 Based on our demonstrated inhibition of DPP-4 activity, NPY levels increased in the HF-SAX group as expected, although not to the pathologic levels observed in HF animals. Limited data support a role for PDE3 regulation of NPY in E, Global longitudinal end-systolic strain was decreased in both HF and HF-SAX compared to the CON group. This effect of HF was enhanced in HF-TAD animals. Global circumferential and radial endsystolic strain was significantly decreased in HF-TAD animals compared to all other groups (*P<0.05 vs CON, † P<0.05 vs HF and HF-SAX). F through H, LV torsion. There was no difference in absolute torsion between groups (F). Torsion normalized to chamber length and septum (G) or LV (H) remodeling was increased in HF animals compared to CON. This effect of heart failure was prevented in the HF-TAD and HF-SAX groups (*P<0.05 vs CON, HF-TAD, and HF-SAX) 2DST indicates 2-dimensional speckle tracking; CON, control; HF, heart failure; LV, left ventricular; SAX, saxagliptin; TAD, tadalafil. hypothalamic neurons 39 ; however, to the best of our knowledge this study is the first to demonstrate alteration of systemic NPY levels following chronic PDE5 inhibition. Our results suggest targeting of the NPY regulatory axis could hold therapeutic potential for limiting pathological fibrotic remodeling in heart failure. We observed numerous indicators of diastolic dysfunction in the HF group at both the organ and cellular level. The current data and previous work from our lab support a mechanistic role for mitochondrial dysfunction, increased LV fibrosis, impaired calcium handling, and increased intrinsic cardiomyocyte stiffness regarding this dysfunction. 16, 18, 19 Interestingly, neither drug treatment prevented the aortic banding-induced increase in EDPVR despite inhibition of increased collagen deposition and maintenance of normal mitochondrial function by saxagliptin. This finding could be attributed to decreased phosphorylation of the large elastic cytoskeletal protein titin. Phosphorylation of titin by PKG decreases passive stiffness in cardiac myofibrils, and recent evidence has shown that increased passive stiffness in isolated cardiomyocytes from human HFpEF patients is associated with reduced cGMP levels and subsequent PKG activity. [7] [8] [9] Contrary to these findings, cGMP levels and PKG activity were unaltered in the HF group of the current study compared to CON. Combined with previous findings from our lab demonstrating titin isoforms do not shift in our model (ie, the N2BA:N2B ratio does not change), 18 we can reasonably speculate that increased titin stiffness as a result of decreased PKG activity was not a likely factor contributing to our results. Saxagliptin treatment did prevent pacinginduced decreases in resting cardiomyocyte sarcomere length and was associated with changes to LV mechanics considered beneficial during early and late diastole. The lack of enhanced mechanics associated with atrial systole in the HF-SAX group may be due to improved early diastolic mechanics related to passive filling, negating the need for augmentation of filling during late diastole. From a systolic perspective, saxagliptin was also effective at preserving aspects of normal LV and cellular function. Although it did not prevent the reduced longitudinal systolic strain commonly observed in HFpEF patients, [40] [41] [42] which is known to correlate with higher LV filling pressures, lower cardiac output, and worse New York Heart Association functional class, 40 treatment with saxagliptin attenuated or prevented alterations to LV systolic function at the whole heart and cellular level observed in the HF group. Attenuation of the heightened contractile state often seen under resting conditions in HFpEF may be due to the preservation or improvement of normal LV diastolic cellular mechanics, myocardial collagen deposition, mitochondrial function, and cardiomyocyte diastolic function in HF-SAX animals despite an increase in the EDPVR. Thus, the combined effect of these mechanisms in the HF-SAX group may be to preserve normal LV end-diastolic volume and diastolic filling, supporting optimal thick filament-to-thin filament geometry to sustain the Frank-Starling mechanism resulting in a normal systolic state (ie, the myocardium is not operating at "maximum" in order to maintain resting cardiac output). This idea is manifest in HFpEF as a loss of cardiac reserve in response to stress (eg, exercise, activities of daily living), which we have previously observed in this model. 23 Overall, our data show saxagliptin prevented HF-specific alterations to LV structure and function at the organ and cellular level that suggest cardiac output is protected by maintaining normal integration of systole and diastole during the cardiac cycle. Changes to LV function observed following tadalafil treatment are more difficult to interpret. The HF-TAD group presented features of the "systolic paradox" often found in HFpEF including normal ejection fraction, stroke volume, and increased LV contractility (ESPVR and PRSW; shown by our lab 23 and others 30 in aortic-banded swine) in concert with reduced longitudinal, circumferential, and radial systolic mechanics. It is worthwhile to note that changes to systolic mechanics and cardiomyocyte function were greater than those observed in the HF group, implying systolic function may be more impaired in HF-TAD animals. It is reasonable to speculate that reductions in systolic strain following treatment with tadalafil may be a reflection of cellular processes promoting a more lusitropic state. However, if this were the case it is difficult to reconcile why strain rates during early diastole were reduced beyond levels observed in HF animals. Furthermore, increased late diastolic strain values equivalent to those observed in the HF group and pacing-induced diastolic dysfunction at the cellular level provide additional support of diastolic impairment in HF-TAD animals. Thus, it is unlikely tadalafil protected normal integrated cardiac function similar to that observed in the HF-SAX group. Rather, considered alongside early evidence of mitochondrial dysfunction, our functional and morphological data imply that treatment with tadalafil impaired diastolic function to a greater degree than observed in HF animals. In total, our data do not support the efficacy of tadalafil for improving cardiac dysfunction in HFpEF.
A primary strength of our study is the use of in vivo methodology in a large animal model that more closely mimics the human condition, providing translational impact. Less is known about cardiac signal transduction in large mammals, despite the significant differences between large and small mammalian hearts including include life span, heart rate, Ca 2+ handling, tolerance for myocardial injury, and rate of progression of cardiac remodeling. 43 The 47 The results from our study did not completely reproduce the findings of Takimoto et al. 6 Although direct comparisons of the studies above are tempting, more importantly these differences provide a reminder that the translation of previous work in rodents to larger mammals and/or humans is not inconsequential and should not be assumed.
Limitations
Although the amino acid sequence of the BNP N-terminus in both humans and pigs is consistent with the substrate specificity of DPP-4, circulating levels of BNP are considerably lower in pigs compared to humans 48 and this feature of our model should be considered in interpreting our results. Our results showed plasma BNP and ANP levels were unchanged across groups, implying the beneficial effect of saxagliptin on fluid accumulation in the lungs was not dependent on unbalanced natriuretic peptide levels. However, our interpretation of these data is limited by methodology, as the radioimmunoassay used in the current study detects both BNP and BNP 3-32 (or total BNP) and does not allow determination of the ratio of intact to cleaved BNP products. To the best of our knowledge, ours is the first study to demonstrate the beneficial effects of saxagliptin on a clinical characteristic of heart failure (lung congestion) in a large animal model of experimental HFpEF.
While both tadalafil and saxagliptin treatment altered the cGMP-PKG-PDE5 signaling axis, neither ultimately translated into an increase in PKG activity. Despite the doses of each drug being determined prior to the study using pharmacokinetic experiments to establish optimal oral administration equivalent to human standards, our findings could be interpreted to suggest the doses of each drug were suboptimal for the pig. Conversely, we could also reason that the saxagliptin dose was appropriate but given the demonstrated plasticity of PDE5 in our study, was ultimately ineffective in increasing net cGMP levels due to increased cGMP catabolism evident as increased PDE5 activity. Similarly, the 2.5-fold increase in cGMP expression in the HF-TAD group could be interpreted as evidence that our tadalafil dose was also appropriate. The lack of a subsequent increase in downstream PKG signaling in HF-TAD animals could be inferred as: (1) the observed increase in cGMP levels was insufficient to stimulate downstream PKG activity; or (2) the activity of other phosphodiesterases such as PDE1 or PDE2 may have compensated for the inhibition of PDE5 by tadalafil. Indeed, both PDE1 and PDE2 have been shown to regulate the hydrolysis of cGMP. 49 Although outside the focus of the current study, our results suggest ideal therapeutic value could be gained from simultaneous administration of both drugs in parallel. Our results also demonstrated that cGMP-PKG-PDE5 levels and activity were unchanged in the HF group, a finding not entirely inconsistent with human literature. The cGMP-PKG-PDE5 signaling axis has been hypothesized to contribute to the pathophysiology of human HF. 6, [50] [51] [52] However, this finding is not definitive in a setting of human HFpEF 5, 9 where clinical data have failed to show benefits previously reported in multiple animal models. 47, 50 For example, van Heerebeek et al 9 found very low levels of cGMP and corresponding PKG activity in human HFpEF left ventricle that was not ascribed to PDE5 upregulation. Regardless, our findings imply that alterations to the cGMP-PKG-PDE5 signaling axis are not fundamental to the development or maintenance of HF in our animal model. Instead, our data suggest that the beneficial effects of saxagliptin on cardiac function may be mediated through reduced DPP-4 activity resulting in attenuation of circulating NPY levels. 
Conclusions
Chronic treatment with tadalafil and saxagliptin induced distinct changes in LV function and remodeling at both the organ and cellular level during the development of heart failure in a clinically relevant aortic-banded miniature swine model displaying key characteristics of HFpEF. Aortic banding caused similar levels of concentric hypertrophy in all groups, although both saxagliptin and tadalafil prevented increased LV collagen deposition. Decreased fibrotic remodeling was correlated with the attenuation of increased NPY plasma levels. Each drug differentially altered the cGMP-PKG-PDE5 signaling axis, with tadalafil increasing myocardial cGMP levels and saxagliptin increasing PDE5 activity. However, . E, Quantification of the area above the curve of the Ca 2+ -induced swelling traces in isolated cardiac mitochondria was unchanged between groups (CsA, cyclosporine-A). F, Ca 2+ -retention capacity was decreased in the HF group compared to CON (*P<0.05 vs CON), demonstrating increased susceptibility to Ca 2+ -induced mitochondrial permeability transition (an early indicator of mitochondrial dysfunction). CON indicates control; HF, heart failure; SAX, saxagliptin; TAD, tadalafil. saxagliptin appears to be a superior candidate for the treatment of HFpEF when considering its comprehensive effects on integrated LV systolic and diastolic function.
